Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up
MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. The company faces high capital requirements for modest revenue gains, but has a substantial cash reserve to sustain operations. FDA approval of CASGVEY validates MaxCyte's platform, with potential multi-billion dollar opportunities and significant future revenue.
MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2024 Earnings Call August 6, 2024 4:30 PM ET Company Participants Scott Feinberg - Investor Relations Maher Masoud - President and Chief Executive Officer Doug Swirsky - Chief Financial Officer Conference Call Participants Hannah Hefley - Stephens Julie Simmonds - Panmure Liberum Steven Mah - TD Cowen Matt Larew - William Blair Jack Siedow - Craig-Hallum Capital Group Paul Cuddon - Deutsche Numis Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to MaxCyte Second Quarter Earnings Conference Call.
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago.
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
MaxCyte (MXCT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
